Hospital-related cost of sepsis: A systematic review

Journal of Infection

Volumn 74, Issue 2, 2017, Pages 107-117

  Arefian, Habibollah ^a   Heublein, Steffen ^a   Scherag, André ^a   Brunkhorst, Frank Martin ^a   Younis, Mustafa Z ^b   Moerer, Onnen ^c   Fischer, Dagmar ^d   Hartmann, Michael ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b JACKSON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cost; Sepsis; Septic shock; Septicemia; Severe sepsis

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; GEOGRAPHIC DISTRIBUTION; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MEDICAL LITERATURE; PEER REVIEW; POPULATION RESEARCH; REVIEW; SEPSIS; SEPTIC SHOCK; SEPTICEMIA; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; ECONOMICS; MICROBIOLOGY; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; QUALITY-ADJUSTED LIFE YEARS; SEPSIS; SHOCK, SEPTIC;

EID: 85007143788     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2016.11.006     Document Type: Review

References (55)

1. 1 Lagu, T., Rothberg, M.B., Shieh, M.S., Pekow, P.S., Steingrub, J.S., Lindenauer, P.K., Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 40 (2012), 754–761, 10.1097/CCM.0b013e318232db65.
2. 2 Fleischmann, C., Scherag, A., Adhikari, N.K.J., Hartog, C.S., Tsaganos, T., Schlattmann, P., et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 193 (2015), 259–272, 10.1164/rccm.201504-0781OC.
3. 3 Torio, C.M., Andrews, R.M., National inpatient hospital costs: the most expensive conditions by payer, 2011: statistical brief #160. Healthcare Cost and Utilization Project (HCUP) statistical briefs. 2006, United States Agency for Health Care Policy and Research, Rockville, MD.
4. 4 Cohen, J., Vincent, J.-L., Adhikari, N.K.J., Machado, F.R., Angus, D.C., Calandra, T., et al. Sepsis: a roadmap for future research. Lancet Infect Dis 15 (2015), 581–614, 10.1016/S1473-3099(15)70112-X.
5. 5 Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ, 346, 2013, f1049, 10.1136/bmj.f1049.
6. 6 Akers, J., University of York, NHS Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. 2009, Centre for Reviews and Dissemination, York.
7. 7 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8 (2010), 336–341, 10.1016/j.ijsu.2010.02.007.
8. 8 Reuters, Thomson, Journal citation reports., 2011 Available at: http://thomsonreuters.com/products_services/science/science_products/a-z/journal_citation_reports Consulted 12/12/15.
9. 9 Bone, R.C., Balk, R.A., Cerra, F.B., Dellinger, R.P., Fein, A.M., Knaus, W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 (1992), 1644–1655, 10.1378/chest.101.6.1644.
10. 10 National Center for Health Statistics, International classification of diseases, ninth revision, clinical modification (ICD-9-CM). 2015 Available at: http://www.cdc.gov/nchs/icd/icd9cm.htm Consulted 12/12/15.
11. 11 Organisation for Economic Co-operation and Development, PPPs and exchange rates organisation for economic co-operation and development. 2015 Available at: http://stats.oecd.org/Index.aspx?querytype=view&queryname=221 Consulted 12/12/15.
12. 12 Organisation for Economic Co-operation and Development, Consumer prices: consumer prices – annual inflation organisation for economic co-operation and development. 2015 Available at: http://stats.oecd.org/Index.aspx?querytype=view&queryname=221# Consulted 12/12/15.
13. 13 World Bank Group, The World Bank [website]. 2015 Available at: http://data.worldbank.org/ Consulted 12/12/15.
14. 14 National Bureau of Statistics, National bureau of statistics [website]. 2015 Available at: http://www.nigerianstat.gov.ng/ Consulted 12/12/15.
15. 15 Drummond, F., Methods for the economic evaluation of health care programmes. 2005, Oxford University Press, Oxford.
16. 16 Adrie, C., Alberti, C., Chaix-Couturier, C., Azoulay, E., De Lassence, A., Cohen, Y., et al. Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost. J Crit Care 20 (2005), 46–58, 10.1016/j.jcrc.2004.10.005.
17. 17 Alvarez, J., Mar, J., Varela-Ledo, E., Garea, M., Matinez-Lamas, L., Rodriguez, J., et al. Cost analysis of real-time polymerase chain reaction microbiological diagnosis in patients with septic shock. Anaesth Intensive Care 40 (2012), 958–963.
18. 18 Balamuth, F., Weiss, S.L., Neuman, M.I., Scott, H., Brady, P.W., Paul, R., et al. Pediatric severe sepsis in U.S. children's hospitals. Pediatr Crit Care Med 15 (2014), 798–805, 10.1097/pcc.0000000000000225.
19. 19 Berto, P., Ronco, C., Cruz, D., Melotti, R.M., Antonelli, M., Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy. Blood Purif 32 (2011), 331–340, 10.1159/000333826.
20. 20 Cheng, B., Xie, G., Yao, S., Wu, X., Guo, Q., Gu, M., et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 35 (2007), 2538–2546, 10.1097/01.ccm.0000284492.30800.00.
21. 21 Davies, A., Ridley, S., Hutton, J., Chinn, C., Barber, B., Angus, D.C., Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia 60 (2005), 155–162, 10.1111/j.1365-2044.2004.04068.x.
22. 22 Dhainaut, J.F., Payet, S., Vallet, B., Franca, L.R., Annane, D., Bollaert, P.E., et al. Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care, 11, 2007, R99, 10.1186/cc6116.
23. 23 Eber, M.R., Laxminarayan, R., Perencevich, E.N., Malani, A., Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med 170 (2010), 347–353, 10.1001/archinternmed.2009.509.
24. 24 Ernst, F.R., Malatestinic, W.N., Linde-Zwirble, W.T., Evaluating the clinical and financial impact of severe sepsis with Medicare or other administrative hospital data. Am J Health Syst Pharm 63 (2006), 575–581, 10.2146/ajhp050214.
25. 25 Giamarellos-Bourboulis, E.J., Mylona, V., Antonopoulou, A., Tsangaris, I., Koutelidakis, I., Marioli, A., et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother 69 (2014), 1111–1118, 10.1093/jac/dkt475.
26. 26 Goodwin, A.J., Rice, D.A., Simpson, K.N., Ford, D.W., Frequency, cost, and risk factors of readmissions among severe sepsis survivors. Crit Care Med 43 (2015), 738–746, 10.1097/ccm.0000000000000859.
27. 27 Green, C., Dinnes, J., Takeda, A.L., Cuthbertson, B.H., Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Int J Technol Assess Health Care 22 (2006), 90–100, 10.1017/S0266462306050884.
28. 28 Hartman, M.E., Linde-Zwirble, W.T., Angus, D.C., Watson, R.S., Trends in the epidemiology of pediatric severe sepsis. Pediatr Crit Care Med 14 (2013), 686–693, 10.1097/PCC.0b013e3182917fad.
29. 29 Huang, D.T., Clermont, G., Dremsizov, T.T., Angus, D.C., Implementation of early goal-directed therapy for severe sepsis and septic shock: a decision analysis. Crit Care Med 35 (2007), 2090–2100, 10.1097/01.CCM.0000281636.82971.92.
30. 30 Jiang, S.P., Zhu, Z.Y., Ma, K.F., Zheng, X., Lu, X.Y., Impact of pharmacist antimicrobial dosing adjustments in septic patients on continuous renal replacement therapy in an intensive care unit. Scand J Infect Dis 45 (2013), 891–899, 10.3109/00365548.2013.827338.
31. 31 Jones, A.E., Troyer, J.L., Kline, J.A., Cost-effectiveness of an emergency department-based early sepsis resuscitation protocol. Crit Care Med 39 (2011), 1306–1312, 10.1097/CCM.0b013e31821201be.
32. 32 Judd, W.R., Stephens, D.M., Kennedy, C.A., Clinical and economic impact of a quality improvement initiative to enhance early recognition and treatment of sepsis. Ann Pharmacother 48 (2014), 1269–1275, 10.1177/1060028014541792.
33. 33 Karlsson, S., Ruokonen, E., Varpula, T., Ala-Kokko, T.I., Pettila, V., Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med 37 (2009), 1268–1274, 10.1097/CCM.0b013e31819c13ac.
34. 34 Lagu, T., Rothberg, M.B., Nathanson, B.H., Hannon, N.S., Steingrub, J.S., Lindenauer, P.K., Contributors to variation in hospital spending for critically ill patients with sepsis. Healthc (Amst) 1 (2013), 30–36, 10.1016/j.hjdsi.2013.04.005.
35. 35 Lagu, T., Rothberg, M.B., Shieh, M.S., Pekow, P.S., Steingrub, J.S., Lindenauer, P.K., What is the best method for estimating the burden of severe sepsis in the United States?. J Crit Care, 27, 2012, 10.1016/j.jcrc.2012.02.004 414.e411–414.e419.
36. 36 Micek, S., Johnson, M.T., Reichley, R., Kollef, M.H., An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. BMC Infect Dis, 12, 2012, 56, 10.1186/1471-2334-12-56.
37. 37 Mouncey, P.R., Osborn, T.M., Power, G.S., Harrison, D.A., Sadique, M.Z., Grieve, R.D., et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 372 (2015), 1301–1311, 10.1056/NEJMoa1500896.
38. 38 Nissenson, A.R., Dylan, M.L., Griffiths, R.I., Yu, H.T., Dean, B.B., Danese, M.D., et al. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am J Kidney Dis 46 (2005), 301–308, 10.1053/j.ajkd.2005.04.019.
39. 39 Noritomi, D.T., Ranzani, O.T., Monteiro, M.B., Ferreira, E.M., Santos, S.R., Leibel, F., et al. Implementation of a multifaceted sepsis education program in an emerging country setting: clinical outcomes and cost-effectiveness in a long-term follow-up study. Intensive Care Med 40 (2014), 182–191, 10.1007/s00134-013-3131-5.
40. 40 Page, D.B., Donnelly, J.P., Wang, H.E., Community-, healthcare-, and hospital-acquired severe sepsis hospitalizations in the university healthsystem consortium. Crit Care Med 43 (2015), 1945–1951, 10.1097/ccm.0000000000001164.
41. 41 Riou Franca, L., Launois, R., Le Lay, K., Aegerter, P., Bouhassira, M., Meshaka, P., et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. Int J Technol Assess Health Care 22 (2006), 101–108, 10.1017/S0266462306050896.
42. 42 Ruth, A., McCracken, C.E., Fortenberry, J.D., Hall, M., Simon, H.K., Hebbar, K.B., Pediatric severe sepsis: current trends and outcomes from the Pediatric Health Information Systems Database. Pediatr Crit Care Med 15 (2014), 828–838, 10.1097/pcc.0000000000000254.
43. 43 Sadique, M.Z., Grieve, R., Harrison, D.A., Cuthbertson, B.H., Rowan, K.M., Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?. Crit Care, 15, 2011, R228, 10.1186/cc10468.
44. 44 Shah, S.S., Hall, M., Srivastava, R., Subramony, A., Levin, J.E., Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 49 (2009), 1369–1376, 10.1086/606048.
45. 45 Shorr, A.F., Micek, S.T., Jackson, W.L. Jr., Kollef, M.H., Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?. Crit Care Med 35 (2007), 1257–1262, 10.1097/01.ccm.0000261886.65063.cc.
46. 46 Silverman, L.Z., Hoesel, L.M., Desai, A., Posa, P., Purtill, M.A., Brandt, M.M., It takes an intensivist. Am J Surg 201 (2011), 320–323, 10.1016/j.amjsurg.2010.09.013 discussion 323.
47. 47 Sogayar, A.M., Machado, F.R., Rea-Neto, A., Dornas, A., Grion, C.M., Lobo, S.M., et al. A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics 26 (2008), 425–434, 10.2165/00019053-200826050-00006.
48. 48 Suarez, D., Ferrer, R., Artigas, A., Azkarate, I., Garnacho-Montero, J., Goma, G., et al. Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain. Intensive Care Med 37 (2011), 444–452, 10.1007/s00134-010-2102-3.
49. 49 Talmor, D., Greenberg, D., Howell, M.D., Lisbon, A., Novack, V., Shapiro, N., The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med 36 (2008), 1168–1174, 10.1097/CCM.0b013e318168f649.
50. 50 Vaughan-Sarrazin, M.S., Bayman, L., Cullen, J.J., Costs of postoperative sepsis: the business case for quality improvement to reduce postoperative sepsis in veterans affairs hospitals. Arch Surg 146 (2011), 944–951, 10.1001/archsurg.2011.78.
51. 51 Vogel, T.R., Dombrovskiy, V.Y., Carson, J.L., Graham, A.M., Lowry, S.F., Postoperative sepsis in the United States. Ann Surg 252 (2010), 1065–1071, 10.1097/SLA.0b013e3181dcf36e.
52. 52 Walkey, A.J., Wiener, R.S., Hospital case volume and outcomes among patients hospitalized with severe sepsis. Am J Respir Crit Care Med 189 (2014), 548–555, 10.1164/rccm.201311-1967OC.
53. 53 McLaughlin, A.M., Hardt, J., Canavan, J.B., Donnelly, M.B., Determining the economic cost of ICU treatment: a prospective “micro-costing” study. Intensive Care Med 35 (2009), 2135–2140, 10.1007/s00134-009-1622-1.
54. 54 Moerer, O., Schmid, A., Hofmann, M., Herklotz, A., Reinhart, K., Werdan, K., et al. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 28 (2002), 1440–1446, 10.1007/s00134-002-1429-9.
55. 55 Singer, M., Deutschman, C.S., Seymour, C., Shankar-Hari, M., Annane, D., Bauer, M., et al. THe third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315 (2016), 801–810, 10.1001/jama.2016.0287.